Evidence map›Paper›PMID 34177913›Full record

ArticleFrontiers in immunology2021

Sagun Parakh, Ashan Musafer, Sabrina Paessler, Tom Witkowski, Connie S N Li Wai Suen, Candani S A Tutuka, Matteo S Carlino, Alexander M Menzies, Richard A Scolyer, Jonathan Cebon and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Biochemistry and biophysics reports · 2026
    Review
  2. Article
  3. Review
  4. International journal of molecular sciences · 2025
    Article
  5. Review
  6. Investigation ofTurkish journal of obstetrics and gynecology · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Sagun ParakhMedical Oncology Unit, Austin Health, Melbourne, VIC, Australia.
Ashan MusaferOlivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.
Sabrina PaesslerOlivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.
Tom WitkowskiOlivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.
Connie S N Li Wai SuenDepartment of Mathematics and Statistics, La Trobe University, Melbourne, VIC, Australia.
Candani S A TutukaOlivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.
Matteo S CarlinoDepartment of Medical Oncology, Westmead and Blacktown Hospitals, Sydney, NSW, Australia.
Alexander M MenziesMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.
Richard A ScolyerMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.
Jonathan CebonMedical Oncology Unit, Austin Health, Melbourne, VIC, Australia.
Alexander DobrovicOlivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.
Georgina V LongMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.
Oliver KleinMedical Oncology Unit, Austin Health, Melbourne, VIC, Australia.
Andreas BehrenOlivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.
Olivia Newton-John Cancer Wellness & Research Centre · AULa Trobe University · AUMelanoma Institute Australia · AURoyal North Shore Hospital · AURoyal Prince Alfred Hospital · AUThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A significant number of patients (pts) with metastatic melanoma do not respond to anti-programmed cell death 1 (PD1) therapies. Identifying predictive biomarkers therefore remains an urgent need. We retrospectively analyzed plasma DNA of pts with advanced melanoma treated with PD-1 antibodies, nivolumab or pembrolizumab, for five PD-1 genotype single nucleotide polymorphisms (SNPs): PD1.1 (rs36084323, G>A), PD1.3 (rs11568821, G>A), PD1.5 (rs2227981, C>T) PD1.6 (rs10204225, G>A) and PD1.9 (rs2227982, C>T). Clinico-pathological and treatment parameters were collected, and presence of SNPs correlated with response, progression free survival (PFS) and overall survival (OS). 115 patients were identified with a median follow up of 18.7 months (range 0.26 - 52.0 months). All were Caucasian; 27% BRAF V600 mutation positive. At PD-1 antibody commencement, 36% were treatment-naïve and 52% had prior ipilimumab. The overall response rate was 43%, 19% achieving a complete response. Overall median PFS was 11.0 months (95% CI 5.4 - 17.3) and median OS was 31.1 months (95% CI 23.2 - NA). Patients with the G/G genotype had more complete responses than with A/G genotype (16.5%

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorDrug Resistance, NeoplasmFemaleGenotypeHumansImmune Checkpoint InhibitorsMaleMelanomaMiddle AgedPolymorphism, Single NucleotideProgrammed Cell Death 1 ReceptorProgression-Free SurvivalRetrospective StudiesBiomarkers, TumorImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptorimmunotherapymetastatic melanomaPD1polymorphismpredictive biomarker

Identifiers

PMID34177913
PMCPMC8220213
OpenAlexW3169661477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.